Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration

Ying Jiang(Nanjing Agricultural University), Ralph A. Nixon(Nathan Kline Institute for Psychiatric Research), John Alam(Hispanics in Philanthropy), Philip Scheltens(Amsterdam University Medical Centers), Afina W. Lemstra(Amsterdam Neuroscience), John F. Smiley(Nathan Kline Institute for Psychiatric Research), Niels D. Prins, Stephen N. Gomperts(Harvard University), Shivakumar Subbanna(Nathan Kline Institute for Psychiatric Research), Sandipkumar Darji(Nathan Kline Institute for Psychiatric Research), Philip Stavrides(Nathan Kline Institute for Psychiatric Research), John Harrison(King's College London), Sandeep Malampati(Nathan Kline Institute for Psychiatric Research), Cynthia Bleiwas(Nathan Kline Institute for Psychiatric Research), Monika Pawlik(Nathan Kline Institute for Psychiatric Research), Paul Maruff(The University of Melbourne), Amanda Gardner, Charlotte E. Teunissen(Amsterdam Neuroscience), James Peddy(Nathan Kline Institute for Psychiatric Research), Ursula A. Germann, Balapal S. Basavarajappa(Nathan Kline Institute for Psychiatric Research), Anna Pensalfini(Nathan Kline Institute for Psychiatric Research), Dun‐Sheng Yang(Nathan Kline Institute for Psychiatric Research), Hui‐May Chu, Kelly Blackburn
Nature Communications
September 21, 2022
Cited by 58


Related Papers